title: [Is there any relation between diabetes therapy and cancer risk?].
abstract: Type 2 diabetes is associated with increased risk of cancer. This risk is related to HbA1 increase and this influence is present also in prediabetes and in nondiabetics with HbA1c in upper normal range. In last 2 years, it was concluded that that the specific antidiabetic therapy could influence the cancer risk. In this review we show that reduction of HbA1c does not change cancer risk. Most important is the risk reduction of cancer risk by metformin. Insulin therapy and the use ofsulphonylurea related drugs, increases the risk of cancer. This risk can be eliminated in the combination with metformin. Other published results including the suspected effect related to the use of glargine, pioglitazone, sitagliptine and exenatide are inconsistent and analysis of long term effects of these drugs is necessary. The large discussion in many publications shows the important role of FDA and EMA. This agencies do not suspend drugs without consistent evaluation of results.
authors.affiliation: III. interní klinika 1. lékarské fakulty UK a VFN Praha. svacinas@lf1.cuni.cz
authors.forename: S
authors.initials: S
authors.lastname: Svacina
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced*; D012306:Risk
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents